HDL Does Not Protect Some Chronically Ill Patients from Heart Disease

In normal individuals, the main HDL protein, apolipoprotein A-I (Apo A-I), has an amphipathic structure suited for transport of lipids. It readily interacts with the ATP-binding cassette transporter ABCA1, the SR-B1 scavenger receptor, and activates the enzyme lecithin-cholesterol acyl transferase (LCAT), which is critical for HDL maturation. It also has antioxidant and anti-inflammatory properties, along with the HDL-associated enzymes paraoxonase, platelet activating factor acetylhydrolase (PAF), and glutathione peroxidase. Regarding the HDL lipid moiety, an atheroprotective role has been recognized for lysosphingolipids, particularly sphingosine-1-phosphate (S1P).

Reviewing the latest studies on HDL, the authors found that all of HDL's atheroprotective functions disappear from the dysfunctional plasma HDLs of subjects with systemic inflammation, coronary heart disease, diabetes, and chronic renal disease. They highlighted the emerging notion that the quality of the HDL particles has more predictive power than their quantity. This has stimulated further exploration of the HDL proteome, already revealing unsuspected pro- or anti-atherogenic proteins and peptides associated with HDL.

"For many years, HDL has been viewed as good cholesterol and has generated a false perception that the more HDL in the blood, the better,” said first author Dr. Angelo Scanu, professor of biochemistry and molecular biology at the University of Chicago (IL, USA). "It is now apparent that subjects with high HDL are not necessarily protected from heart problems and should ask their doctor to find out whether their HDL is good or bad.”

Related Links:
University of Chicago